XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.1

Segments (Tables)

3 Months Ended

Mar. 31, 2023

Summary of Segment Profit

a. Segment information:

		Three months ended March 31,
		2023
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,766			$	1,184			$	492
Gross profit			812				655				262
R&D expenses			156				53				20
S&M expenses			223				187				98
G&A expenses			102				70				31
Other income			(1	)			§				(1	)
Segment profit		$	332			$	345			$	114

§ Represents an amount less than $0.5 million.

		Three months ended March 31,
		2022
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,737			$	1,156			$	492
Gross profit			890				694				286
R&D expenses			143				58				20
S&M expenses			245				196				97
G&A expenses			112				59				29
Other income			(11	)			§				(40	)
Segment profit		$	402			$	381			$	179

§ Represents an amount less than $0.5 million.

Schedule Of Consolidated Income Before Income Tax

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March 31, 2023 and 2022:

		Three months ended
		March 31,
		2023				2022
		(U.S. $ in millions)
North America profit		$	332			$	402
Europe profit			345				381
International Markets profit			114				179
Total reportable segments profit			791				962
Profit (loss) of other activities			(6	)			52
Total segments profit			785				1,013
Amounts not allocated to segments:
Amortization			165				200
Other assets impairments, restructuring and other items			96				128
Intangible assets impairments			178				149
Legal settlements and loss contingencies			233				1,124
Other unallocated amounts			112				127
Consolidated operating income (loss)			2				(713	)
Financial expenses, net			260				258
Consolidated income (loss) before income taxes		$	(258	)		$	(971	)

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three months ended March 31, 2023 and 2022:

North America		Three months ended March 31,
		2023				2022
		(U.S. $ in millions)
Generic products		$	824			$	899
AJOVY			49				36
AUSTEDO			170				154
BENDEKA® and TREANDA®			63				82
COPAXONE			76				86
Anda			424				342
Other			160				139
Total		$	1,766			$	1,737

Europe		Three months ended March 31,
		2023				2022
		(U.S. $ in millions)
Generic products		$	932			$	876
AJOVY			36				30
COPAXONE			59				72
Respiratory products			68				71
Other			89				107
Total		$	1,184			$	1,156

International markets		Three months ended March 31,
		2023				2022
		(U.S. $ in millions)
Generic products		$	400			$	388
AJOVY			10				6
COPAXONE			12				10
Other			70				88
Total		$	492			$	492

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration